Insomnia News and Research

Latest Insomnia News and Research

New drug approved for COPD by the FDA

The U.S. FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD). COPD affects smokers and the elderly and leads to severe difficulty in breathing, chronic cough and excessive mucus production. An exacerbation can last up to several weeks and result in a decline in lung function and increased risk of death, and it may be associated with severe anxiety, the FDA says.

1 Mar 2011

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration approved EDARBI for the treatment of hypertension, or high blood pressure, in adults.

27 Feb 2011

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.

24 Feb 2011

UCI study details benefits of physical activity, diet, relationships, fun and spirituality

Getting more exercise, spending time outdoors and helping others are among the activities that can be as effective as drugs or counseling in treating an array of mental illnesses, including depression and anxiety, according to a UC Irvine study.

23 Feb 2011

USPTO issues Notice of Allowance to Somaxon's Silenor patent application

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for claims in U.S. patent application no. 11/781,165.

23 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

Energy drink induced psychosis in mentally ill

A new study that has appeared in the latest publication of the Medical Journal of Australia has shown that the mentally ill should avoid energy drinks as they may result in a trigger of psychosis.

21 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Patients receiving cancer treatment may experience skin, hair, nail problems

A cancer diagnosis and subsequent treatment, which commonly includes chemotherapy or radiation, can be taxing physically and emotionally on any patient. If that is not enough, dermatologists are cautioning patients receiving cancer treatment and cancer survivors that they may experience a host of skin, hair or nail problems as a direct result of their therapy that may require additional treatment by a dermatologist.

5 Feb 2011

ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc.. ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

Study finds increased prescription drug abuse among teens

Illicit drugs like marijuana, cocaine and heroin have always been a parent's nightmare. But perfectly legal and easily accessible prescription medications are now the recreational drugs of choice for many teenagers, prompting physicians at Johns Hopkins Children's Center to urge pediatricians to screen specifically for their abuse during routine visits.

4 Feb 2011

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.

1 Feb 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

The University of Massachusetts Medical School and Lundbeck Inc. today announced a research collaboration aimed at further development of a targeted therapy to slow or halt the progression of Huntington's disease.

29 Jan 2011

UMMS, Lundbeck enter research collaboration to develop targeted therapy for HD

The University of Massachusetts Medical School and Lundbeck today announced a research collaboration aimed at further development of a targeted therapy to slow or halt the progression of Huntington's disease.

28 Jan 2011

Triad alcohol prep pads with ARIXTRA Starter Kits not to be used

GlaxoSmithKline (GSK) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names. The Triad Group recall has been initiated due to concerns about potential microbial contamination of the alcohol products with Bacillus cereus that could potentially lead to life-threatening infections.

25 Jan 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011